Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Clinical Trial

Research Support, Non-U.S. Gov't

Multicenter Study

Review

Randomized Controlled Trial

Comparative Study

Clinical Trial, Phase II

Case Reports

Research Support, N.I.H., Extramural

Clinical Trial, Phase III

Letter

Clinical Trial, Phase I

Systematic Review

Research Support, U.S. Gov't, P.H.S.

Observational Study

Publication Year

From

Quick links

Individual year

2025

2024

2023

2022

2020

2019

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Idarubicin""[mesh_terms]

70 Results

Searching titles within these results

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero, E Jabbour, M Konopleva, S O'Brien, Z Estrov, G Borthakur, D Thomas, S Pierce, M Brandt, K Pratz, R Luthra, M Andreeff, H Kantarjian

Leukemia 2014;28(7):1543-5

Free Full Text

Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Tapan M Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D DiNardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R Marx, Caitlin R Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Rabiul Islam, Richard Champlin, Elizabeth Shpall, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian

American journal of hematology 2023;98(11):1711-1720

Free Full Text

Abstract

Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.

Kane Langdon, Stevie Cosentino, Olivia Wawryk

Cancer reports (Hoboken, N.J.) 2024;7(3):e2035

Free Full Text

Abstract

The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.

Yukun Li, Rong Lin, Xiaodong Peng, Xuesi Wang, Xinmeng Liu, Linling Li, Rong Bai, Songnan Wen, Yanfei Ruan, Xing Chang, Ribo Tang, Nian Liu

Oxidative medicine and cellular longevity 2022;2022():3659278

Free Full Text

Abstract

Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

Saskia K Klein, Bart J Biemond, Marinus H J van Oers

Annals of hematology 2008;86(12):917-8

Free Full Text

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

Pau Montesinos, Joaquín Díaz-Mediavilla, Guillermo Debén, Virginia Prates, Mar Tormo, Vicente Rubio, Inmaculada Pérez, Isolda Fernández, Maricruz Viguria, Chelo Rayón, José González, Javier de la Serna, Jordi Esteve, Juan M Bergua, Concha Rivas, Marcos González, Jose D González, Silvia Negri, Salut Brunet, Bob Lowenberg, Miguel A Sanz

Haematologica 2009;94(9):1242-9

Free Full Text

Abstract

GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.

Roberto Latagliata, Massimo Breccia, Paola Fazi, Marco Vignetti, Francesco Di Raimondo, Marco Sborgia, Donatella Vincelli, Anna Candoni, Flavia Salvi, Serena Rupoli, Giovanni Martinelli, Maria Grazia Kropp, Anna Tonso, Adriano Venditti, Lorella Melillo, Giuseppe Cimino, Maria Concetta Petti, Giuseppe Avvisati, Francesco Lo-Coco, Franco Mandelli

British journal of haematology 2011;154(5):564-8

Full Text

Abstract

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

Francesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, Massimo Breccia, Eugenio Gallo, Alessandro Rambaldi, Francesca Paoloni, Giuseppe Fioritoni, Felicetto Ferrara, Giorgina Specchia, Giuseppe Cimino, Daniela Diverio, Erika Borlenghi, Giovanni Martinelli, Francesco Di Raimondo, Eros Di Bona, Paola Fazi, Antonio Peta, Alberto Bosi, Angelo M Carella, Francesco Fabbiano, Enrico M Pogliani, Maria C Petti, Sergio Amadori, Franco Mandelli

Blood 2010;116(17):3171-9

Free Full Text

Abstract

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

Steven M Kornblau, Deborah E Banker, Derek Stirewalt, Danny Shen, Elizabeth Lemker, Srdan Verstovsek, Zeev Estrov, Stefan Faderl, Jorge Cortes, Miloslav Beran, C Ellen Jackson, Wenjing Chen, Elihu Estey, Frederick R Appelbaum

Blood 2007;109(7):2999-3006

Free Full Text

Abstract

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Sanam Loghavi, Yesid Alvarado, Musa Yilmaz, Farhad Ravandi-Kashani, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D DiNardo, Naveen Pemmaraju, Nitin Jain, Kayleigh R Marx, Hagop Kantarjian, Tapan M Kadia, Guillermo Garcia-Manero, Hannah Goulart, Himachandana Atluri, Fadi G Haddad, Caitlin Rausch

Cancer 2025;131(8):e35840

Full Text

Abstract

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

Kenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, Heather Baxter, John Catalano, Timothy Brighton, Devinder Gill, Paul Eliadis, Douglas Joshua, Paul Cannell, Anthony P Schwarer, Simon Durrant, Anne Gillett, Jerry Koutts, Kerry Taylor, John Bashford, Christopher Arthur, Arno Enno, Lindsay Dunlop, Jeff Szer, Michael Leahy, Surender Juneja, Graham A R Young

Blood 2005;105(2):481-8

Free Full Text

Abstract

Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience.

Gilles Freyer, Alain Lortholary, Corinne Delcambre, Thierry Delozier, Gilles Piot, Françoise Genin, Eric Pujade-Lauraine

Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):17-23

Full Text

Abstract

Tetraploidy acute promyelocytic leuemia with double t(15;17)/PML-RARA, a case report with review of literature.

Samir M Dalia, Pedro Horna, Ling Zhang

International journal of clinical and experimental pathology 2015;7(8):5363-8

Free Full Text

Abstract

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.

Elihu H Estey, Francis J Giles, Miloslav Beran, Susan O'Brien, Sherry A Pierce, Stefan H Faderl, Jorge E Cortes, Hagop M Kantarjian

Blood 2002;99(11):4222-4

Free Full Text

Abstract

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Kerry Taylor, John Catalano, Paul Cannell, Noemi Horvath, Sandra Deveridge, Peter Browett, Tim Brighton, Li Chong, Francisca Springall, Juliet Ayling, Alberto Catalano, Shane Supple, Marnie Collins, Juliana Di Iulio, John Reynolds

Haematologica 2012;97(2):227-34

Free Full Text

Abstract

Results: 1 – 15 / 70

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Idarubicin""[mesh_terms]

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.

The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.

Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience.

Tetraploidy acute promyelocytic leuemia with double t(15;17)/PML-RARA, a case report with review of literature.

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Results for
""Idarubicin""[mesh_terms]